- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
In Focus: The Treatment of Multiple Myeloma
A recent study found evidence suggesting that genetically modifying immune cells might effectively treat multiple myeloma.
A recent study found evidence suggesting that genetically modifying immune cells might effectively treat multiple myeloma. The rare disease is a cancer of the plasma cells, the type of white blood cells present in bone marrow. It is diagnosed in an estimated 24,000 new patients a year, and currently has no cure.
Researchers from the Ohio State University Comprehensive Cancer Centers (OSUCCC) modified the human immune cell known as T lymphocyte (T cell) to target the molecule CS1, which is found in more than 95% of myeloma cells. The modified cell attacks the molecule and kills the cells affected with CS1.
“Despite current drugs and use of bone marrow transplantation, multiple myeloma is still incurable, and almost all patients eventually relapse,” said study researcher Craig Hofmeister, MD, MPH, assistant professor of medicine and a member of the OSUCCC — James Translational Therapeutics Program. “This study presents a novel strategy for treating multiple myeloma, and we hope to bring it to patients as part of a phase 1 clinical trial as soon as possible.”
Clinical trials like those Dr Hofmeister mentioned are a valuable way for researchers to explore cost-effective treatments. According to a recent panel discussion from The American Journal of Managed Care, finding cost-effective treatments for the rare disease is crucial.
“It’s really important to try and figure out what type of myeloma a patient may have, and the best way to treat, because there are some very low-risk types of myeloma that can be managed very well with standard therapies and then there are more aggressive types that really do need these newer agents and combinations,” said Anne Quinn Young, MPH, vice president, Development and Strategic Partnerships, Multiple Myeloma Research Foundation.
The full panel is available here.
Around the Web
A Form of Immune Therapy Might be Effective for Multiple Myeloma [Medical Xpress]
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Texas Oncology to Roll Out Canopy for ePROs After Head-to-Head Pilot
March 18th 2025Debra Patt, MD, PhD, MBA, executive vice president of Public Policy and Strategy for Texas Oncology, said the practice received positive feedback from nurses and patients during a pilot that concluded in February.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
